Acura Pharmaceuticals, Inc.
Other OTCTotal Valuation
Acura Pharmaceuticals, Inc. carries a market capitalization of 6,600.00, placing it among publicly traded companies globally. Its enterprise value stands at 32.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6,600.00 |
| Enterprise Value | 32.68M |
Share Statistics
Acura Pharmaceuticals, Inc. currently has 65.09M shares outstanding.
| Shares Outstanding | 65.09M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 18.12, and the price-to-book ratio stands at 182.85.
| PE Ratio | N/A |
| PS Ratio | 18.12 |
| PB Ratio | 182.85 |
| P/TBV Ratio | 182.85 |
| P/FCF Ratio | -38.16 |
| P/OCF Ratio | -38.16 |
Enterprise Valuation
| EV / Sales | 20.91 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 31.93 |
Financial Position
Acura Pharmaceuticals, Inc. maintains a current ratio of 0.72, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 112.36, indicating elevated leverage, while an interest coverage ratio of -5.62 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.72 |
| Quick Ratio | 0.43 |
| Debt / Equity | 112.36 |
| Debt / EBITDA | -0.18 |
| Interest Coverage | -5.62 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -67.72 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 234.53 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Acura Pharmaceuticals, Inc.'s stock has declined approximately -66.66667% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | -66.66667% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Acura Pharmaceuticals, Inc. generated 1.56M in revenue and converted that into -879,000.00 in net income, yielding earnings per share of -0.02. EBITDA reached -1.12M, while operating income came in at -1.21M.
| Revenue | 1.56M |
| Gross Profit | N/A |
| Operating Income | -1.21M |
| Pretax Income | -879,000.00 |
| Net Income | -879,000.00 |
| EBITDA | -1.12M |
| EBIT | -1.21M |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
Acura Pharmaceuticals, Inc. holds 65,000.00 in cash and equivalents against 200,000.00 in total debt, resulting in a net debt position of 85,000.00. Total book value stands at 178,000.00, with working capital of -143,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 65,000.00 |
| Total Debt | 200,000.00 |
| Net Debt | 85,000.00 |
| Equity (Book Value) | 178,000.00 |
| Book Value Per Share | 0.00 |
| Working Capital | -143,000.00 |
Cash Flow
Acura Pharmaceuticals, Inc. produced -742,000.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -742,000.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -742,000.00 |
| FCF Per Share | -0.01 |
Margins
Acura Pharmaceuticals, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -77.67 and net profit margin of -56.24 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -77.67 |
| Pretax Margin | -56.24 |
| Profit Margin | -56.24 |
| EBITDA Margin | -71.91 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -1.21 |
| FCF Yield | -2.62 |
Stock Splits
Acura Pharmaceuticals, Inc.'s most recent stock split took place on August 28, 2015 with a 5:1 split ratio.
| Last Split Date | 8/28/2015 |
| Split Ratio | 5:1 |
Scores
Acura Pharmaceuticals, Inc. posts an Altman Z-Score of -609.43, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -609.43 |